SCHEMBL4355299

SCHEMBL4355299

O=C1N=C(N2CCN(c3ccccc3F)CC2)SC1=Cc1cccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.65
RAB9A P51151 1/20 0.65
HTT P42858 4/20 0.63
KMT2A Q03164 4/20 0.58
MEN1 O00255 2/20 0.58
SENP1 Q9P0U3 1/20 0.52
ALDH1A1 P00352 6/20 0.51
MAPT P10636 5/20 0.51
GLA P06280 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
AMY1A P0DUB6 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4355295 1.00 NPC1 (0.65) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4351282 0.84 SENP1 (0.71) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4351281 0.84 SENP1 (0.71) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4350166 0.83 NPC1 (0.59) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4350162 0.83 NPC1 (0.59) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4347177 0.82 MAPT (0.62) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4359797 0.82 NPC1 (0.58) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4347179 0.82 MAPT (0.62) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4359795 0.82 NPC1 (0.58) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4353850 0.81 HTT (0.55) NPC1RAB9AHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 NPC1 326/4885RAB9A 3151/4885HTT 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.